Leonard Schleifer

Last updated

Leonard S. Schleifer
Born1953 (age 70–71)
NationalityAmerican
Education Cornell University (BS)
University of Virginia (MD, PhD)
Occupation(s)Doctor
Businessman
Known forFounder and CEO of Regeneron Pharmaceuticals
SpouseHarriet Partel Schleifer
ChildrenAdam Schleifer
David Schleifer
Parent(s)Florence Schacht Schleifer
Charles Baker Schleifer

Leonard S. Schleifer (born 1953) is an American businessman and is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals.

Contents

Early life and education

He was born and raised in a Jewish family, the son of Florence and Charles Baker Schleifer, [1] in Queens, New York. [2] His father was a sweater manufacturer and World War II codebreaker. [1] He graduated with a B.S. from Cornell University and a MD-PhD from the University of Virginia where he studied under future Nobel Laureate, Alfred G. Gilman. [2] He then worked at New York Hospital where he trained to become a neurologist and also served as a junior faculty member. [2]

Career

Noticing that the biotechnology company Genentech was conducting state-of-the-art research but not on diseases of the nervous system, Schleifer was determined to get into the biotechnology business. [2] Choosing not to accept Gilman's efforts to recruit him as an academic, he found a sponsor in George Sing, a venture capitalist at Merrill Lynch, and obtained $1 million in seed capital. He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded Regeneron Pharmaceuticals. [2] After several years of trying to recruit research doctors many of whom preferred to work in academia or for large corporations, they developed their first drug to treat Lou Gehrig’s disease. It was a failure as was their second drug to treat obesity. [2] Thereafter, they invited the former Merck & Co. CEO Roy Vagelos to be the chairman of their company and to help to turn the company around. He implemented two strategic changes; only invest in drugs in which the biology of the disorder is fully understood; and do not underestimate the importance of human testing to ensure that what works in the laboratory will also work in the real world. [3]

Eylea

As CEO of Regeneron, Schleifer oversaw the "approval and growth of high-priced drugs." [4] In 2011, Regeneron's first successful drug was Eylea for age-related macular degeneration. [4] Eylea prevented leaky blood vessels in the eye from causing blindness. [2] [3] He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. [2] The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 [3] making Schleifer a billionaire. [2] In 2014 Eylea grossed $1.735 billion. [4]

As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the "annual collaborative report" from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of "200 highest-paid CEOs of large publicly traded companies." He ranked first in the list of biopharmaceutical executives with the highest total compensation. [4]

COVID-19 drugs

The subject is currently working on a multi-center, double-blind, Phase 2/3 trial with the partnership Sanofi, to evaluate the antibody agent, Kevzara(TM) for hospitalized patients starting in March 2020, as well as, working on the development of a novel, multi-antibody cocktail to be used as both a prevention of SARS-CoV-2 and treatment for infected patients. [5] [6] Regeneron's apparent privileged access of its experimental Covid-19 therapeutic to Donald Trump and members of the Trump administration drew criticism over ethical concerns. [7] [8]

Personal life

He is married to Harriet (née Partel) Schleifer; they have two children, Adam and David. [9] [10] Harriet has an undergraduate degree from Cornell University, two graduate degrees in education from the University of Virginia and a J.D. degree from St. John's University School of Law. [9] She also serves as a member of the Board of Governors of American Jewish Committee [9] and as president of her synagogue. [11]

Schleifer has known U.S. President Donald Trump for some years, as he was a member of Trump’s golf club in Westchester County, New York. [12]

His son Adam was one of many candidates for the nomination in the 2020 Democratic Primary for New York's 17th congressional district. [13]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development presently known as Fortrea is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is spin-off from Labcorp, which employs more than 70,000 people worldwide.

<span class="mw-page-title-main">George Yancopoulos</span> American biomedical scientist (born 1959)

George D. Yancopoulos is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

<span class="mw-page-title-main">Lonza Group</span> Swiss pharmaceutical and biotech company

Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals.

Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.

<span class="mw-page-title-main">Pascal Soriot</span> French businessman

Sir Pascal Claude Roland Soriot is a French-born Australian businessman and chief executive officer (CEO) of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.

<span class="mw-page-title-main">Dupilumab</span> Drug used to treat allergic diseases

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.

Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Operation Warp Speed</span> US program to accelerate COVID-19 vaccine efforts

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.

<span class="mw-page-title-main">Rick Bright</span> American immunologist and whisteblower

Rick Arthur Bright is an American immunologist, vaccine researcher, and public health official. He was the director of the Biomedical Advanced Research and Development Authority (BARDA) from 2016 to 2020. In May 2020, he filed a whistleblower complaint, alleging that the Trump administration ignored his early warnings about the COVID-19 pandemic and illegally retaliated against him by ousting him from his role and demoting him to a position at the National Institutes of Health. On October 6, 2020, Bright resigned from the government. On November 9 he was named a member of President-elect Joe Biden's coronavirus advisory board.

<span class="mw-page-title-main">Michelle McMurry-Heath</span> American Immunologist

Michelle McMurry-Heath is a medical doctor, immunologist, and from June 2020 until October 2022 served as chief executive officer for the Biotechnology Innovation Organization (BIO).

<span class="mw-page-title-main">Casirivimab/imdevimab</span> Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

References

  1. 1 2 New York Times: "Paid Notice: Deaths SCHLEIFER, CHARLES BAKER December 4, 2011
  2. 1 2 3 4 5 6 7 8 9 Forbes: "Regeneron Chief Leonard Schleifer Becomes A Billionaire After 25 Year Search For New Drugs" by Matthew Herper February 25, 2014
  3. 1 2 3 Matthew Herper (September 2, 2013), "How Two Guys From Queens Are Changing Drug Discovery", Forbes, retrieved November 19, 2015
  4. 1 2 3 4 Nicole Gray (May 29, 2015), "Biopharma execs have big presence among top-paid CEOs", BioPharma Dive, retrieved November 19, 2015
  5. ↑ Regeneron Pharmaceudicals, (March 17, 2020). "Investor Relations and Media: REGENERON Announces Important Advances in novel COVID-19 Antibody Program". Press Release. Regeneron Pharmaceuticals Retrieved March 29, 2020.
  6. ↑ Washington Journal. Steve Scully, host. (March 29, 2020). "Dr. Leonard Schleifer Discusses Developing COVID-19 Drug Therapies." C-Span website Retrieved March 29, 2020.
  7. ↑ Stolberg, Sheryl Gay (December 10, 2020). "Sheryl Gay Stolberg (December 9, 2020) "Trump and Friends Got Coronavirus Care Many Others Couldn't" The New York Times". The New York Times.
  8. ↑ "Alison Bateman-House, et al. (October 8, 2020) "Trump's Regeneron Treatment Is a Tangled Ethical Mess" Barron's".
  9. 1 2 3 American Jewish Committee: "Harriet Schleifer" Archived March 30, 2014, at the Wayback Machine retrieved March 29, 2014
  10. ↑ New York Times: "Paid Notice: Deaths PARTEL, RUBIN" February 4, 2008
  11. ↑ Mount Vernon Inquirer: "Westchester Jewish Council 40th Anniversary Gala to Honor Harriet P. Schleifer and William H. Schrag" [ permanent dead link ] retrieved May 5, 2017
  12. ↑ Tomazin, Farrah (October 3, 2020). "Trump, 'racing against the virus', receives experimental antibodies". The Sydney Morning Herald . Retrieved October 3, 2020.
  13. ↑ Lungariello, Mark (November 25, 2019). "Adam Schleifer, 'Operation Varsity Blues' prosecutor, joins field for Nita Lowey's seat". Lohud. Retrieved April 20, 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.